The health equity conversation has exploded across healthcare and adjacent industries, as we saw patient care disparities exacerbated following the COVID-19 outbreak. The pandemic provided an inflection point around the need to reshape healthcare delivery and improve access to innovative solutions. The opportunity is ripe for biopharma, advocacy, academia and the medical community to converge, accelerating treatment development and the pursuit of cures for all patients suffering from serious diseases. Bristol Myers Squibb and experts will explore patient centricity; ways to operate more inclusively within healthcare, from research to commercialization; address how collaboration may help solve contributing factors to inequities; and the importance of equal representation in patient care.